INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›science›UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation
science

UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation

By Info60 US Desk•Summary of reporting by M2 Pharma•1d ago•0 views•
30 September 2026 - UTR Therapeutics Inc, a New York-based biotech company, announced on Tuesday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 3'UTRMYCN M1...
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

Why this robot burns the tips off cotton plants with a Laser

Why this robot burns the tips off cotton plants with a Laser

Interesting Engineering

Clark Atlanta Lands Nearly $10M Pentagon Grant to Grow AI Research

Clark Atlanta Lands Nearly $10M Pentagon Grant to Grow AI Research

Hoodline

NASA Studies Ancient Scottish Rocks To Unlock Mars’ Lost Past

NASA Studies Ancient Scottish Rocks To Unlock Mars’ Lost Past

The Daily Galaxy

AI predicts pancreatic cancer years before diagnosis

AI predicts pancreatic cancer years before diagnosis

Earth.com

Deployable Energy to test its nuclear battery at INL's DOME

Deployable Energy to test its nuclear battery at INL's DOME

Postregister

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!